IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i3p1724-d740954.html
   My bibliography  Save this article

Symptomatology of Fibromyalgia Syndrome in Men: A Mixed-Method Pilot Study

Author

Listed:
  • Ilga Ruschak

    (Internal Medicine Unit, Sant Pau i Santa Tecla Hospital, 43003 Tarragona, Spain
    Faculty and Department of Nursing, Rovira i Virgili University, 43003 Tarragona, Spain)

  • Loren Toussaint

    (Department of Psychology, Luther College, Decorah, IA 52101, USA)

  • Lluís Rosselló

    (Rheumatologist at the Santa Maria Hospital, 25198 Lleida, Spain)

  • Carina Aguilar Martín

    (Unit of Research Support, Foundation University Institute for Primary Care Research (IDIAP) Jordi Gol, 43500 Tortosa, Spain
    Evaluation Unit, Primary Care Direction in Terres de l’Ebre, Institut Català de la Salut (ICS), 43500 Tortosa, Spain)

  • José Fernández-Sáez

    (Unit of Research Support, Foundation University Institute for Primary Care Research (IDIAP) Jordi Gol, 43500 Tortosa, Spain
    Faculty and Department of Nursing, Rovira i Virgili University, 43500 Tortosa, Spain)

  • Pilar Montesó-Curto

    (Master in Aging and Health, Department of Medicine, Rovira i Virgili University, 43201 Reus, Spain
    Primary Care in Institut Català de la Salut (ICS), 43500 Tortosa, Spain)

Abstract

Fibromyalgia syndrome (FMS) is characterized by generalized chronic musculoskeletal pain, fatigue, and sleep disturbance, as well as cognitive, somatic, and other symptoms. Most people affected by FMS are women, and studies analyzing this condition in men are scarce. In this study, we discuss the physical and psychological symptoms of FMS in men, analyze the possible side effects of pharmacological therapies, and explore the impact of the illness comparing these results between the different classification groups according to sociodemographic variables (marital status, level of education, employment situation and number of people living at home). We used a sequential exploratory mixed method (MM). Qualitative information was obtained from two focus groups (n = 10). Structured questionnaires were administered to 23 men affected by FMS. The mean age of the participants was 51.7 years (SD = 9.64). The most common drugs used were antidepressants and anxiolytics (86.9%), followed by non-steroidal anti-inflammatory drugs (82.6%) and opioids (60.9%). Current level of pain was high (8.2; SD = 1.1), while perceived health and satisfaction with pharmacological treatments were low (4.6; SD = 2.6 and 3.5; SD = 3.2, respectively). The impact of FMS measured using the Fibromyalgia Impact Questionnaire (FIQ) was very high at 88.7 (SD = 8.2). Six categories related with symptoms and side effects of the medication were observed in the qualitative data: (1) main physical symptoms, (2) mood disorders, (3) insomnia and non-restorative sleep, (4) cognitive disturbance, (5) hypersensitivity, and (6) symptoms secondary to opioids. Pain and fatigue were the symptoms most often mentioned by the participants (70% and 80%, respectively). Other important symptoms were anxiety, depression, and memory and sleep disorders. The consumption of opioids causes further unwanted symptoms such as drowsiness and dependence, which makes it difficult for patients to perform basic everyday activities. We believe it is vitally important to continue investigating this symptomatology in order to improve diagnosis and treatment for these patients.

Suggested Citation

  • Ilga Ruschak & Loren Toussaint & Lluís Rosselló & Carina Aguilar Martín & José Fernández-Sáez & Pilar Montesó-Curto, 2022. "Symptomatology of Fibromyalgia Syndrome in Men: A Mixed-Method Pilot Study," IJERPH, MDPI, vol. 19(3), pages 1-16, February.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:3:p:1724-:d:740954
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/3/1724/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/3/1724/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:3:p:1724-:d:740954. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.